Hualv Biology: Shareholder Suqian Huaxin Investment plans to reduce its holdings by no more than 1%.

Hualv Biological Announcement: Specific shareholder Suqian Huaxin Investment Management Center holds 1.872 million shares of the company before its initial public offering, accounting for 1.56% of the total share capital excluding repurchased shares. They plan to reduce their holdings by no more than 1.872 million shares through centralized bidding within 3 months after the disclosure date of this announcement. The number of shares reduced in any continuous 90-day period should not exceed 1% of the total share capital excluding repurchased shares, and the reduction price will be determined based on market prices.